APS treatment was associated with significant changes in the expression of genes involved in apoptosis and immune cell activation, notably CASP3, PTPRC and ELANE (Porter and Jänicke, 1999; Hussar, 2022; Chua and Laurent, 2006; Cohen, 1997). The gene discussed is ELANE; the disease is autoimmune polyendocrinopathy.